LegUpRx Injectable Tirzepatide

Who this is for — and who it isn't

Strong fit if you:

• Want a dual GIP/GLP-1 agonist (tirzepatide) rather than the GLP-1-only mechanism of semaglutide — clinically, tirzepatide produces larger average weight loss
• Are price-sensitive and prefer cash-pay over insurance-mediated brand-name access
• Don't have insurance coverage for Zepbound or Mounjaro, or have a high deductible
• Are comfortable understanding and accepting the 503A compounding regulatory landscape and the active Lilly litigation environment
• Tolerate injections (this is the injectable form — see the microdose alternative below for a less aggressive dose)
• Live in any U.S. state (all 50 covered)

Look elsewhere if you:

• Have insurance that covers Zepbound or Mounjaro — use it; copays under most commercial plans are $25–$100/month
• Have a personal or family history of medullary thyroid carcinoma (MTC) or MEN-2 (black-box warning applies to tirzepatide as well)
• Want the regulatory cover of FDA-approved medication and are unwilling to accept the compounded-product regulatory risk — use LillyDirect Zepbound at $349–$499/mo cash-pay starting dose
• Are seeking the lowest absolute price and the efficacy of tirzepatide vs semaglutide doesn't matter to you — LegUpRx Sublingual Semaglutide at $174/mo is the cost leader, just on the GLP-1-only mechanism
• Are pregnant, lactating, or planning pregnancy

The 4-dimensional grade

VYTAL.RX grades every provider on four axes. Read our methodology for how we weight them.

The all-in 12-month math

For context, here's what the same molecule costs elsewhere over twelve months:

• Zepbound via LillyDirect (2.5mg starter): $349 × 12 = $4,188 — cheaper than this on the starter dose only; jumps to $499–$1,059 once titrated to therapeutic doses
• Zepbound mid-dose cash via LillyDirect: $499 × 12 = $5,988 — matches LegUpRx at this tier, but brand-name and FDA-approved
• Zepbound list price (uninsured, no program): ~$1,059 × 12 = $12,708 — over 2× this review's price
• Mounjaro list price (T2D-only indication): ~$1,135 × 12 = $13,620 — branded, indication-mismatched for weight loss

→ See the full math across 10 providers in our cost calculator

What the intake actually asks (we completed it)

VYTAL.RX Editors completed the LegUpRx tirzepatide intake on May 14, 2026. Here's the factual report:

Time to complete: ~11 minutes (slightly longer than the semaglutide intake due to the DKA screen and injection-technique acknowledgement). Clinician review timeline: ~28 hours from submission to approval notification, in our test.

Improvement areas we flagged for the team:

1. Cardiac history should be required, not optional — tirzepatide's GIP receptor activity has a less-mature cardiovascular safety profile than long-established GLP-1-only agonists. Surface it harder.
2. Acknowledge the regulatory landscape in the intake itself — patients should be told before paying that they are entering a 503A patient-specific compounding program for a molecule whose compounding legal status has been contested. Current intake assumes regulatory literacy.
3. Mental-health screening still too brief — same flag as the semaglutide review. Tirzepatide's appetite-suppression effect is stronger, making mood-effect surveillance more relevant, not less.

Compounding & sourcing

• Compounding type: 503A patient-specific. Each prescription is compounded for the individual patient based on the clinician's order — not bulk-manufactured.
• Pharmacy: U.S.-based, LegitScript-certified compounding pharmacy. Specific pharmacy partner disclosed at order confirmation.
• API source: Pharmaceutical-grade tirzepatide. Certificate of analysis available on request from the dispensing pharmacy.
• Formulation: Injectable tirzepatide combined with adjunct additives (typical formulations include niacinamide or vitamin B12 to improve tolerability). Specific additive list confirmed at order.
• Delivery format: Sterile injectable vial with provided syringes. Subcutaneous self-administration. Cold-chain shipping included.
• State licensing: All 50 U.S. states.

The regulatory landscape, in detail

This section is what separates an honest review from a marketing page. Compounded tirzepatide sits in a different regulatory bucket than compounded semaglutide, and patients deserve to understand it before paying.

The shortage list and its expiration. Tirzepatide was placed on the FDA drug-shortage list during 2023–2024 due to Lilly's inability to meet brand-name demand. Under FDA Section 503B, this allowed bulk compounding for general distribution while the shortage persisted. In late 2024 and through 2025, the FDA determined the shortage was resolved and removed tirzepatide from the list. After that, 503B bulk compounding for general distribution is no longer permitted.

What's still legal as of May 2026. 503A patient-specific compounding remains legal for tirzepatide. This is the pathway LegUpRx uses: each prescription is compounded based on an individual clinician's order for a specific patient, with documented medical necessity (typically: brand-name product not commercially viable for the patient at the prescribed dose or with the prescribed adjuncts). This is the most defensible legal posture for compounded tirzepatide today.

Lilly litigation. Eli Lilly has filed lawsuits against multiple compounding pharmacies and telehealth platforms over tirzepatide marketing and dispensing. Most filings target marketing claims (suggesting equivalence to FDA-approved Zepbound/Mounjaro) and 503B-adjacent activity rather than properly executed 503A patient-specific compounding. The legal environment can shift. Treat the regulatory landscape as a tail risk: the program is operating legally today, and could be disrupted with limited notice if litigation expands or FDA further restricts the 503A category.

What this means for you. If you start this program, you're accepting that supply could be interrupted by regulatory or litigation action. Most cash-pay GLP-1 patients accept this; brand-name Zepbound via LillyDirect is the regulatorily safest fallback at $349–$499/mo cash. We mark the regulatory column down by one full point relative to the semaglutide review for this reason.

How it stacks against the competition

The honest read: LegUpRx is priced at the same point as LillyDirect's mid-dose cash tier. The trade is regulatory cover (Zepbound is FDA-approved, but starter doses only at $349) versus dose flexibility (LegUpRx prescribes the actual dose your clinician orders, without the LillyDirect cash-pay program's dose-tier markup structure). If you're going to titrate to 7.5mg+, the brand-name path gets meaningfully more expensive than this review's price; if you're staying on 2.5mg, LillyDirect's starter is cheaper and FDA-approved.

What we'd change

1. Surface the regulatory landscape in the intake. The patient should understand 503A compounding versus 503B and the Lilly litigation context before paying — not after. This is the single biggest improvement opportunity.
2. Make cardiac history required, not optional. Same flag as the semaglutide review; even more relevant here given tirzepatide's GIP activity.
3. Disclose the specific compounding pharmacy on the marketing page. Same trust-signal-hidden-behind-conversion-gate problem as the semaglutide review.
4. Publish the titration schedule on the program page. Tirzepatide titration is more complex than semaglutide (2.5 → 5 → 7.5 → 10 → 12.5 → 15mg typical). Patients should see the schedule before signing up.
5. Add a "what if the program is disrupted" FAQ. Given the regulatory tail risk, patients should know what happens to their care continuity if a future ruling or settlement disrupts dispensing. A brief plan-for-transition note would build trust.

The bottom line, restated

LegUpRx's $499/mo compounded injectable tirzepatide is the cheapest verified legal cash-pay path to the tirzepatide molecule as of May 2026. The intake, sourcing transparency, and screening rigor are on par with the company's semaglutide program, which we previously graded 8.5/10. The grade here lands at 7.8/10 because the regulatory environment for compounded tirzepatide is materially more contested than for semaglutide — not because the provider does anything wrong.

If you have insurance for Zepbound or Mounjaro, use it. If you want the cheapest GLP-1 mechanism and don't need the dual GIP/GLP-1 efficacy, the sublingual semaglutide review is the better entry point at $174/mo. If you specifically want tirzepatide and are willing to accept the regulatory tail risk, this is the cleanest cash-pay path we've verified.

Footnotes

• Pricing source — LegUpRx: LegUpRx published rate via partner catalog, accessed May 15, 2026. May change.
• FDA shortage list status: Tirzepatide was removed from the FDA drug-shortage list in late 2024 / early 2025. Subsequent 503B bulk compounding is no longer permitted.
• 503A vs 503B compounding: 503A covers patient-specific compounding for an individual prescription; 503B covers bulk outsourcing facilities producing finished drugs in advance of prescriptions. Different regulatory frameworks under the Federal Food, Drug, and Cosmetic Act.
• Compounded medications are not FDA-approved. They are legal under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act when produced in compliance with the relevant statute.
• Not medical advice. Consult a licensed clinician before starting any prescription program. Individual results vary. Tirzepatide carries a black-box warning for thyroid C-cell tumors.
• Last updated: 2026-05-15.